Dealbreaker on MSN
Servier boosts presence in rare cancers with $2.5B acquisition of Day One Biopharma
Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, ...
The two-day summit, which brought together policymakers, health experts, and industry leaders, set out to answer one central question: What is the true economic return of health?
Team IMPACT partnerships often last long beyond the 2-year contract between children and the teams that sign them.
The deaths of American troops in the Iran war are resurfacing the hurt felt by families of those lost in previous wars. “I know what they’re feeling — their whole world is falling apart,” one woman ...
The weekend attack brought the death toll to at least 157 people since the administration began targeting the alleged drug ...
"Lori and I mourn with the Pennsylvania State Police family and with all of our law enforcement partners. I’ve directed flags across our Commonwealth to be lowered Monday in hon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results